[Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 2. Pharmacological characterization of 2-alkylsulfonyl-oxyalkylamino-oxazaphosphorine-2-oxides including immunological reaction].
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002066:Busulfan / Q000494:pharmacology / Q000627:therapeutic use; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D003498:Cyclic P-Oxides / Q000494:pharmacology* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005260:Female; D006168:Guinea Pigs; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D007939:Leukemia L1210 / Q000188:drug therapy; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008698:Mesylates / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010078:Oxazines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012517:Sarcoma, Yoshida / Q000188:drug therapy; D013268:Stimulation, Chemical
D000970:Antineoplastic Agents; D003498:Cyclic P-Oxides; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D008698:Mesylates; D009588:Nitrogen Mustard Compounds; D010078:Oxazines; D003520:Cyclophosphamide; D002066:Busulfan